Viking Therapeutics Inc. on Wednesday reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic disorder X-linked adrenoleukodystrophy, or X-ALD.
Viking Therapeutics Inc.’s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatme ...
Viking Therapeutics Inc.'s stock rose 1.4% in premarket trade Wednesday, after the biotech reported positive data from an early-stage trial of a treatment for the rare, and often fatal, metabolic ...